bevacizumab
roche
['triplet']
no trial compared doublet-antiegfr to folfoxiri +/- bev. should triplet be favored in left-sided ras wt tumors? orr similar (50-80%) toxicity post-progression options doublet + anti-egfr preferred. as in this great algorithm by #asco22 
??Medical Oncologist, MSc, PhD. GI/neuroendocrine/GU tumors/breast cancer ??Hospital Universitario UFC-CE, Oncologia D’Or